5 completed, 2 recruiting, 1 terminated. 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Recruiting 2, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow avacopan: new trials by email Literature Review of avacopan trials Research Report on avacopan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) Avacopan, Prednisone, Methylprednisolone (drug) - IgA Nephropathy (IgAN) | Phase 2 | Recruiting | Mayo Clinic | 16 | 2025-06-09 | 2026-10-09 |
| Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) Avacopan, Placebo - Hidradenitis Suppurativa, Acne Inversa | Phase 2 | Completed | Amgen | 435 | 2018-12-21 | 2025-03-17 |
| Controlled Trial Evaluating Avacopan in C3 Glomerulopathy Avacopan, Avacopan Matching Placebo - C3 Glomerulopathy (C3G) | Phase 2 | Completed | Amgen | 57 | 2017-09-29 | 2025-03-13 |
| Complement Inhibition in aHUS Dialysis Patients CCX168 - Atypical Hemolytic Uremic Syndrome | Phase 2 | Terminated | Mario Negri Institute for Pharmacological Research | 6 | 2015-06-04 | 2017-11-14 |
| Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade CCX168 - Immunoglobulin A Nephropathy | Phase 2 | Completed | Amgen | 7 | 2015-03-27 | 2025-03-13 |
| Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids - ANCA-associated Vasculitis | Phase 2 | Completed | Amgen | 42 | 2015-02-04 | 2025-03-13 |
| A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis Placebo, CCX168 - Vasculitis | Phase 2 | Completed | Amgen | 67 | 2011-09-01 | 2025-03-13 |
Glomerulonephritis, IGA (2) · Vasculitis (2) · Abscess (1) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Atypical Hemolytic Uremic Syndrome (1) · Glomerulonephritis, Membranoproliferative (1) · Granulomatosis with Polyangiitis (1) · Hidradenitis Suppurativa (1) · Skin Diseases (1)
Amgen (5) · Mario Negri Institute for Pharmacological Research (1) · Mayo Clinic (1) · Robert Spiera, MD (1)
United States (6) · Belgium (2) · Canada (2) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Sweden (2) · United Kingdom (2) · Austria (1) · Czechia (1) · Denmark (1) · Hungary (1) · Ireland (1) · Poland (1)
Fernando Fervenza, MD (1) · Giuseppe Remuzzi, MD (1) · Lindsay Lally, MD (1) · Nabeel Aslam, MD (1) · Robert F Spiera, MD (1)
PMID 24033923, PMID 33128347, PMID 34852172, PMID 39392695
2014 (2)